This morning, the chief of surgery Y brought a patient whose treatment opinion was completely different from that of the patient’s local doctor, and he couldn’t decide and came to my office. The patient’s basic situation is: female, 73 years old, after surgery for a tumor in the outer upper quadrant of the left breast, medical report: invasive breast cancer of the left breast, tumor diameter 1 cm, left axillary lymph node 1/16 metastasis, ER(+), ER(+), HER-2(-), ki67 14%, has done 4 cycles of chemotherapy with CT protocol. The local doctor suggested the patient to have local radiotherapy, continue chemotherapy for 2 cycles, or use cellular biotherapy if he did not want to continue chemotherapy. Our director Y said frankly that he had not read any breast cancer related books for 5 years and based on his previous knowledge, the patient did not need radiotherapy and chemotherapy was enough, just endocrine therapy. I helped Director Y to compile the patient’s clinical data and then informed that Director Y’s view was correct. The reason was that the patient’s clinical stage was PT1N1M0, the molecular typing was Luminal A, and she was an elderly breast cancer. The patient has already had 4 cycles of CT protocol, chemotherapy is sufficient and no further chemotherapy is needed. No local radiotherapy is needed. Oral endocrine therapy is recommended for 5-10 years. Luminal A is a breast cancer with the best prognosis, and the efficacy of endocrine therapy alone after surgery without chemotherapy is similar to that of chemotherapy followed by endocrine therapy, with significantly different toxic and side effects. Endocrine therapy has less toxic side effects, better quality of life and longer survival time. Therefore, chemotherapy is not recommended for Luminal A patients after surgery, only endocrine therapy and regular medical checkups are needed. 2.The treatment of breast cancer, surgery, radiotherapy, chemotherapy and endocrine therapy are all very mature treatments, each of which has its unique role and clear guidelines. The guidelines for radiotherapy after breast cancer surgery are: after simple mastectomy (irradiation of chest wall and lymphatic drainage area); after radical surgery, pathology confirms that there are more than 4 lymph nodes metastasis; pathology confirms internal breast lymph node metastasis; the primary focus is located in the inner side of the breast with lymph node metastasis. The patient’s lesion was located in the upper outer quadrant of the left breast, and the surgery had been a radical resection with only 1/16 lymph node metastasis; therefore, there was no radiotherapy guideline. 3. Elderly breast cancer is a special group, body aging will bring many organ function degeneration, for example, decreased compensatory capacity of liver and kidney function, which affects the detoxification and excretion of chemotherapy drugs; insufficient gastrointestinal function, which easily increases the increase of adverse reactions of chemotherapy drugs in the digestive tract; defective humoral and cellular immune function, which affects the effect of biological therapy and certain targeted therapies. Therefore the elderly, do not overtreat. Even if you want to do chemotherapy, according to the characteristics of the elderly should be carefully prepared for protection. 4.Cellular biotherapy is a new treatment method other than surgery, radiotherapy, chemotherapy, endocrine therapy and molecular targeted therapy, and there are still many problems to be solved. Among the known factors, cellular biologic therapy cannot replace surgery, radiotherapy, chemotherapy, molecular targeted therapy and endocrine therapy for breast cancer patients. There are no contraindications to cellular biologic therapy in this patient, but it cannot be used to replace endocrine therapy treatment (or chemotherapy).